TNF-α antibody therapy in combination with the T-Cell-specific antibody anti-TCR reverses the diabetic metabolic state in the LEW.1AR1-iddm rat

Diabetes

Volumn 64, Issue 8, 2015, Pages 2880-2891

  Jörns, Anne ^a   Ertekin, Ümüs Gül ^a   Arndt, Tanja ^a   Terbish, Taivankhuu ^a   Wedekind, Dirk ^a   Lenzen, Sigurd ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CD3 ANTIGEN; T LYMPHOCYTE ANTIBODY; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; GLUCOSE BLOOD LEVEL; INSULIN; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; IMMUNOCOMPETENT CELL; INSULIN DEPENDENT DIABETES MELLITUS; MONOTHERAPY; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; THERAPEUTIC INDEX; ANIMAL; BLOOD; DIABETES MELLITUS, TYPE 1; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; LEWIS RAT; MALE; METABOLISM; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD GLUCOSE; C-PEPTIDE; CELL PROLIFERATION; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; INSULIN; MALE; RATS; RATS, INBRED LEW; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84943355943     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1866     Document Type: Article

References (51)

1. Eisenbarth GS. Type I diabetes. Molecular, cellular and clinical immunology [Internet], 2012. Available from http://www.ucdenver.edu/academics/colleges/medicalschool/centers/BarbaraDavis/OnlineBooks/Pages/Type1Diabetes.aspx Accessed 27 March 2015.
2. Knight RR, Kronenberg D, Zhao M, et al. Human b-cell killing by autoreactive preproinsulin-specific CD8 T cells is predominantly granule-mediated with the potency dependent upon T-cell receptor avidity. Diabetes 2013;62:205-213.
3. Jörns A, Arndt T, Meyer zu Vilsendorf A, et al. Islet infiltration, cytokine expression and beta cell death in the NOD mouse, BB rat, Komeda rat, LEW.1AR1- iddm rat and humans with type 1 diabetes. Diabetologia 2014;57:512-521.
4. Arnush M, Scarim AL, Heitmeier MR, Kelly CB, Corbett JA. Potential role of resident islet macrophage activation in the initiation of autoimmune diabetes. J Immunol 1998;160:2684-2691.
5. Jörns A, Günther A, Hedrich HJ, Wedekind D, Tiedge M, Lenzen S. Immune cell infiltration, cytokine expression, and beta-cell apoptosis during the development of type 1 diabetes in the spontaneously diabetic LEW.1AR1/Ztm-iddm rat. Diabetes 2005;54:2041-2052.
6. Matthews JB, Staeva TP, Bernstein PL, Peakman M, von Herrath M; ITNJDRF Type 1 Diabetes Combination Therapy Assessment Group. Developing combination immunotherapies for type 1 diabetes: Recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol 2010;160:176-184.
7. Rydén AK, Wesley JD, Coppieters KT, Von Herrath MG. Non- Antigenic and antigenic interventions in type 1 diabetes. Hum Vaccin Immunother 2014;10: 838-846.
8. Ludvigsson J. Combination therapy for preservation of beta cell function in Type 1 diabetes: new attitudes and strategies are needed! Immunol Lett 2014; 159:30-35.
9. Koulmanda M, Bhasin M, Awdeh Z, et al. The role of TNF- A in mice with type 1- And 2- diabetes. Plos One 2012;7:e33254.
10. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002;2:364-371.
11. Bandzar S, Gupta S, Platt MO. Crohn's disease: A review of treatment options and current research. Cell Immunol 2013;286:45-52.
12. Parameswaran N, Patial S. Tumor necrosis factor- A signaling in macrophages. Crit Rev Eukaryot Gene Expr 2010;20:87-103.
13. Nepom GT, Ehlers M, Mandrup-Poulsen T. Anti-cytokine therapies in T1D: concepts and strategies. Clin Immunol 2013;149:279-285.
14. Plevy SE, Landers CJ, Prehn J, et al. A role for TNF- Alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997;159: 6276-6282.
15. Kalden JR. Anti-TNF therapy: What have we learned in 12 years? Arthritis Res Ther 2011;13(Suppl. 1):S1.
16. Murdaca G, Spanò F, Puppo F. Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: Efficacy and safety. Expert Opin Drug Saf 2014;13:295-305.
17. Murdaca G, Gulli R, Spanò F, et al. TNF- A gene polymorphisms: Association with disease susceptibility and response to anti-TNF- A treatment in psoriatic arthritis. J Invest Dermatol 2014;134:2503-2509.
18. Mastrandrea L, Yu J, Behrens T, et al. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009;32:1244-1249.
19. Arif S, Cox P, Afzali B, et al. Anti-TNFalpha therapy-killing two birds with one stone? Lancet 2010;375:2278.
20. Palazzi C, D'Angelo S, Leccese P, Padula A, Olivieri I. Safety of anti- Tumor necrosis factor agents in psoriatic arthritis - An update. Expert Opin Drug Saf 2014;13:191-196.
21. Donath MY, Hess C, Palmer E. What is the role of autoimmunity in type 1 diabetes? A clinical perspective. Diabetologia 2014;57:653-655.
22. Roep BO, Buckner J, Sawcer S, Toes R, Zipp F. The problems and promises of research into human immunology and autoimmune disease. Nat Med 2012;18: 48-53.
23. Roep BO, Tree TI. Immune modulation in humans: implications for type 1 diabetes mellitus. Nat Rev Endocrinol 2014;10:229-242.
24. Lenzen S. Oxidative stress: The vulnerable beta-cell. Biochem Soc Trans 2008;36:343-347.
25. Jörns A, Akin M, Arndt T, et al. Anti-TCR therapy combined with fingolimod for reversal of diabetic hyperglycemia by β cell regeneration in the LEW.1AR1-iddm rat model of type 1 diabetes. J Mol Med (Berl) 2014;92: 743-755.
26. Sherry NA, Chen W, Kushner JA, et al. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology 2007;148:5136-5144.
27. Ablamunits V, Henegariu O, Hansen JB, et al. Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: Evidence of improved immune regulation. Diabetes 2012;61:145-154.
28. Takiishi T, Korf H, Van Belle TL, et al. Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest 2012;122:1717-1725.
29. Pagni PP, Bresson D, Rodriguez-Calvo T, et al. Combination therapy with an anti-IL-1b antibody and GAD65 DNA vaccine can reverse recent-onset diabetes in the RIP-GP mouse model. Diabetes 2014;63:2015-2025.
30. Lenzen S, Tiedge M, Elsner M, et al. The LEW.1AR1/Ztm-iddm rat: A new model of spontaneous insulin-dependent diabetes mellitus. Diabetologia 2001; 44:1189-1196.
31. Arndt T, Wedekind D, Weiss H, et al. Prevention of spontaneous immunemediated diabetes development in the LEW.1AR1-iddm rat by selective CD8+ T cell transfer is associated with a cytokine shift in the pancreas-draining lymph nodes. Diabetologia 2009;52:1381-1390.
32. Hünig T, Wallny HJ, Hartley JK, Lawetzky A, Tiefenthaler G. A monoclonal antibody to a constant determinant of the rat T cell antigen receptor that induces T cell activation. Differential reactivity with subsets of immature and mature T lymphocytes. J Exp Med 1989;169:73-86.
33. Chatenoud L. Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies? Nat Rev Endocrinol 2010;6:149-157.
34. Aronson R, Gottlieb PA, Christiansen JS, et al.; DEFEND Investigator Group. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: Results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care 2014;37:2746-2754.
35. Matsumoto Y, Tsuchida M, Hanawa H, Abo T. Successful prevention and treatment of autoimmune encephalomyelitis by short- Term administration of anti- T-cell receptor alpha beta antibody. Immunology 1994;81:1-7.
36. Jörns A, Rath KJ, Terbish T, et al. Diabetes prevention by immunomodulatory FTY720 treatment in the LEW.1AR1-iddm rat despite immune cell activation. Endocrinology 2010;151:3555-3565.
37. Bresson D, Togher L, Rodrigo E, et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 2006;116:1371-1381.
38. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010;464:1293-1300.
39. Chatenoud L, Warncke K, Ziegler AG. Clinical immunologic interventions for the treatment of type 1 diabetes. Cold Spring Harb Perspect Med 2012;2:a007716.
40. von Herrath M. Combination therapies for type 1 diabetes: Why not now? Immunotherapy 2010;2:289-291.
41. Sempé P, Bédossa P, Richard MF, Villà MC, Bach JF, Boitard C. Anti- Alpha/beta T cell receptor monoclonal antibody provides an efficient therapy for autoimmune diabetes in nonobese diabetic (NOD) mice. Eur J Immunol 1991;21:1163-1169.
42. Keymeulen B, Walter M, Mathieu C, et al. Four-year metabolic outcome of a randomised controlled CD3- Antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010;53:614-623.
43. Sherry N, Hagopian W, Ludvigsson J, et al.; Protégé Trial Investigators. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011;378:487-497.
44. Herold KC, Gitelman SE, Willi SM, et al. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: A randomised controlled trial. Diabetologia 2013;56:391-400.
45. Katz LH, Kopylov U, Fudim E, et al. Expression of IL-2, IL-17 and TNF- Alpha in patients with Crohn's disease treated with anti-TNF antibodies. Clin Res Hepatol Gastroenterol 2014;38:491-498.
46. Peters MJ. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study: Response to Mastrandrea et al. Diabetes Care 2009;32:e153; author reply e154.
47. Liadis N, Murakami K, Eweida M, et al. Caspase-3-dependent beta-cell apoptosis in the initiation of autoimmune diabetes mellitus. Mol Cell Biol 2005; 25:3620-3629.
48. Khalaileh A, Gonen-Gross T, Magenheim J, et al. Determinants of pancreatic beta-cell regeneration. Diabetes Obes Metab 2008;10(Suppl. 4):128-135.
49. Bonner-Weir S, Li WC, Ouziel-Yahalom L, Guo L, Weir GC, Sharma A. Betacell growth and regeneration: Replication is only part of the story. Diabetes 2010; 59:2340-2348.
50. Schloot NC, Hanifi-Moghaddam P, Aabenhus-Andersen N, et al. Association of immune mediators at diagnosis of type 1 diabetes with later clinical remission. Diabet Med 2007;24:512-520.
51. Demeester S, Keymeulen B, Kaufman L, et al. Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual b-cell function in recent-onset type 1 diabetes. Diabetes Care 2015;38:644-651.